ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026
N-methyl-D-aspartate receptor inhibition protects against obesity-induced kidney disease.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundObesity-associated nephropathy is becoming increasingly prevalent, yet the molecular mechanisms linking metabolic stress to renal dysfunction remain unclear. N-methyl-D-aspartate receptors (NMDARs) are expressed in the kidney and are involved in the pathogenesis of different renal diseases. This study aimed to explore the role of NMDAR in obesity-induced kidney disease (OIKD).
methodsNMDAR expression was assessed in a murine model of OIKD, an in vitro fat-overload model, and in kidney biopsies from chronic kidney disease (CKD) patients. We combined pharmacological inhibition with gain- and loss-of-function strategies: NMDAR antagonists, memantine and MK-801, were tested in vitro and in vivo, while NMDAR was overexpressed and downregulated in cultured proximal tubular epithelial (HK-2) cells to evaluate its contribution to OIKD.
resultsFree fatty acids (FFAs) exposure in HK-2 cells and high-fat diet (HFD) feeding in an OIKD mouse model led to increased GluN1, an essential subunit of NMDAR, accompanied by lipid accumulation and inflammatory responses associated with cellular injury. Kidney biopsies from CKD patients showed elevated GluN1 levels. In vitro, NMDAR antagonism attenuated FFA-induced cellular lipid accumulation and inflammation, regulated cellular redox homeostasis and suppressed FFA-induced p38 phosphorylation. GluN1 overexpression in HK-2 increased inflammatory markers, altered redox-regulating factors and promoted p38 activation. Treatment of cells with the p38 kinase inhibitor reduced FFA-induced GluN1 upregulation and attenuated inflammation. In vivo, NMDAR blockade reduced HFD-driven inflammation and tubular injury, and enhanced antioxidant gene expression.
conclusionOur results demonstrate that renal NMDAR contributes to the pathogenesis of OIKD and underscore the therapeutic potential of targeting this receptor to attenuate inflammation and kidney injury in obesity-associated nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.